Citation: Circulation: Cardiovascular Interventions. 11(10):e007331, 2018 Oct..Journal: Circulation. Cardiovascular interventions.Published: 2018; ISSN: 1941-7640.Full author list: Bennett J; Cutlip DE; Doros G; Garcia-Garcia HM; Gharib EG; Kandzari DE; Koolen JJ; Marcusohn E; Massaro JM; Roguin A; Waksman R.UI/PMID: 30354631.Subject(s): *Absorbable Implants | *Acute Coronary Syndrome/th [Therapy] | *Cardiovascular Agents/ad [Administration & Dosage] | *Drug-Eluting Stents | *Everolimus/ad [Administration & Dosage] | *Percutaneous Coronary Intervention/is [Instrumentation] | *Polymers/ch [Chemistry] | *Sirolimus/ad [Administration & Dosage] | Acute Coronary Syndrome/dg [Diagnostic Imaging] | Acute Coronary Syndrome/mo [Mortality] | Aged | Cardiovascular Agents/ae [Adverse Effects] | Everolimus/ae [Adverse Effects] | Female | Humans | Male | Middle Aged | Percutaneous Coronary Intervention/ae [Adverse Effects] | Percutaneous Coronary Intervention/mo [Mortality] | Prospective Studies | Prosthesis Design | Risk Assessment | Risk Factors | Single-Blind Method | Sirolimus/ae [Adverse Effects] | Time Factors | Treatment OutcomeInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.1161/CIRCINTERVENTIONS.118.007331 (Click here)Abbreviated citation: Circ., Cardiovasc. interv.. 11(10):e007331, 2018 Oct.Local Holdings: Available online from MWHC library: 2008 - present.Abstract: BACKGROUND: Presentation with acute coronary syndromes (ACS) constitutes a high-risk subset of patients with worse outcome after percutaneous coronary intervention. We report clinical outcomes in subjects with ACS from the BIOFLOW V trial (BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions) comparing an ultrathin strut (60 mum) bioresorbable polymer sirolimus-eluting stent (BP-SES) with a thin strut (81 mum) durable polymer everolimus-eluting stent (DP-EES).Abstract: CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02389946.Abstract: CONCLUSIONS: In the ACS subgroup population of the BIOFLOW V study, treatment with BP-SES compared with DP-EES was associated with a significantly lower rate of 12-month target lesion failure, a difference driven by significantly lower periprocedural MI and spontaneous MI. These findings support treatment with an ultrathin strut BP-SES in ACS patients undergoing percutaneous coronary intervention.Abstract: METHODS AND RESULTS: Among 1334 patients randomized to 2:1 treatment with either BP-SES or DP-EES, 677 (50.7%) ACS patients without ST-segment-elevation myocardial infarction (MI; 454 BP-SES and 223 DP-EES) were identified in the retrospective post hoc analysis. The primary end point of 12-month target lesion failure, individual component end points, and stent thrombosis were evaluated. Recurrent MI was defined as a >=50% increase of creatine kinase-myocardial band or in the absence of creatine kinase-myocardial band, troponin >50% increase over previous level and >3x the upper limit of normal). All events were adjudicated by a blinded independent clinical events committee. Overall, baseline clinical, angiographic, and procedural characteristics of the ACS population were similar between the 2 treatment groups. At 12 months, target lesion failure occurred in 5.6% (24/426) of BP-SES patients versus 11.0% (23/209) in DP-EES patients ( P=0.02); target lesion failure composite components were cardiac death, 0% versus 1.0% ( P=0.11); target vessel-related MI, 3.5% versus 9.7% ( P=0.003); and clinically driven target lesion revascularization, 2.8% versus 3.4% ( P=0.80). Spontaneous target vessel MI was 0.5% (2/425) for BP-SES versus 2.4% (5/206) for DP-EES ( P=0.041). Stent thrombosis rates at 1 year were similar (0.5% versus 1.0%; P=0.601).